Gilead opens trial over $20 billion drug

By Scott Graham, From The Recorder Gilead Sciences Inc. and Merck & Co. Inc. went to trial Monday in San Jose over the IP rights to Gilead’s $20 billion hepatitis C drug sofosbuvir. Lawyers for each company lauded the other’s…